KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Invested Capital (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Invested Capital for 6 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 9.27% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 9.27%, and an annual FY2025 reading of $1.1 billion, up 9.27% over the prior year.
  • Invested Capital was $1.1 billion for Q4 2025 at Recursion Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $1.1 billion in Q4 2025 and bottomed at -$233.0 million in Q1 2021.
  • Average Invested Capital over 5 years is $589.7 million, with a median of $513.2 million recorded in 2022.
  • Peak annual rise in Invested Capital hit 503.11% in 2021, while the deepest fall reached 64.82% in 2021.
  • Year by year, Invested Capital stood at $542.9 million in 2021, then decreased by 10.52% to $485.8 million in 2022, then dropped by 4.6% to $463.5 million in 2023, then surged by 125.08% to $1.0 billion in 2024, then grew by 9.27% to $1.1 billion in 2025.
  • Business Quant data shows Invested Capital for RXRX at $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $927.9 million in Q2 2025.